A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Journal of Critical Care

Volumn 57, Issue , 2020, Pages 279-283

  Cortegiani, Andrea ^a   Ingoglia, Giulia ^a   Ippolito, Mariachiara ^a   Giarratano, Antonino ^a   Einav, Sharon ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chloroquine; Coronavirus; COVID 19; Pneumonia; SARS CoV 2

Indexed keywords

ARBIDOL; CHLOROQUINE; HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; LOPINAVIR PLUS RITONAVIR; PLACEBO; ANTIMALARIAL AGENT;

ARTICLE; CLINICAL STUDY; CORONAVIRUS DISEASE 2019; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; NONHUMAN; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS PNEUMONIA; VIRUS REPLICATION; BETACORONAVIRUS; CHINA; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION; PANDEMIC; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; BETACORONAVIRUS; CHINA; CHLOROQUINE; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 85081702276     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2020.03.005     Document Type: Article

References (18)

1. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama, 2020, 10.1001/jama.2020.2648.
2. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R., Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 3 (2003), 722–727.
3. Colson, P., Rolain, J.-M., Raoult, D., Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents, 2020, 105923.
4. https://www.who.int/blueprint/priority-diseases/keyaction/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 Accessed on 2nd March 2020.
5. Gao, J., Tian, Z., Yang, X., Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 2020, 10.5582/bst.2020.01047.
6. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 10.1038/s41422–020–0282–0.
7. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 43, 2020 E019–9.
8. https://lci.rivm.nl/covid-19/bijlage/behandeladvies (Accessed on 6th March 2020).
9. http://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf (Accessed on 6th March 2020).
10. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (Accessed on 5th March 2020).
11. http://www.xinhuanet.com/english/2020-02/28/c_138828090.htm (Accessed on 2th March 2020).
12. Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020, 10.1056/NEJMoa2002032 NEJMoa2002032.
13. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama, 2020, 10.1001/jama.2020.1585.
14. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020, 10.1016/S2213-2600(20)30079-5.
15. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
16. https://www.who.int/blueprint/priority-diseases/key-action/multicenter-adaptive-RCT-of-investigational-therapeutics-for-COVID-19.pdf?ua=1 (Accessed on 6th Mrch 2020).
17. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf (Accessed on 6th March 2020).
18. Lenk, C., Duttge, G., Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 10 (2014), 537–546.